Randomized studies in patients with follicular lymphoma using rituximab plus chemotherapy.
| Reference . | Patients within each FLIPI strata, % low/intermediate/high-risk . | Median age, y . | Follow-up, mo . | Median PFS Control arm, mo . | Median PFS Experimental arm, mo . | Estimated PFS in the experimental arm, % . | Improvement of overall survival . |
|---|---|---|---|---|---|---|---|
| Abbreviations: PFS, progression-free survival; CVP, cyclophosphamide, vincristine, and prednisone; R-CVP, rituximab plus CVP; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MCP, mitoxantrone, chlorambucil, and prednisolone; CHVP+I, cyclophosphamide, doxorubicin, teniposide, and prednisone plus interferon | |||||||
| *CHOP or R-CHOP was followed by autologous stem cell transplantation or interferon. | |||||||
| †MCP and R-MCP were followed by interferon consolidation. | |||||||
| ‡CHVP combined with interferon: 12 chemotherapy courses in the control arm versus 6 in the rituximab containing arm. | |||||||
| Marcus et al21,58 | 19 /41/40 | 52 | 53 | 15 (CVP) | 34 (R-CVP) | 50 (at 3 y) | Yes |
| Hiddemann et al59* | 14 /41/45 | 55 | 18 | 31 (CHOP) | Not reached (R-CHOP) | 80 (at 2 y) | Yes |
| Herold et al19† | 7/37/56 | 59 | 47 | 29 (CHOP) | Not reached (R-MCP) | 71 (at 4 y) | Yes |
| Salles et al60 (updated)‡ | 19/35/46 | 61 | 60 | 35 (CHVP+I) | Not reached (R-CHVP+I) | 53 (at 5 y) | Yes (in high-risk patients) |
| Reference . | Patients within each FLIPI strata, % low/intermediate/high-risk . | Median age, y . | Follow-up, mo . | Median PFS Control arm, mo . | Median PFS Experimental arm, mo . | Estimated PFS in the experimental arm, % . | Improvement of overall survival . |
|---|---|---|---|---|---|---|---|
| Abbreviations: PFS, progression-free survival; CVP, cyclophosphamide, vincristine, and prednisone; R-CVP, rituximab plus CVP; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MCP, mitoxantrone, chlorambucil, and prednisolone; CHVP+I, cyclophosphamide, doxorubicin, teniposide, and prednisone plus interferon | |||||||
| *CHOP or R-CHOP was followed by autologous stem cell transplantation or interferon. | |||||||
| †MCP and R-MCP were followed by interferon consolidation. | |||||||
| ‡CHVP combined with interferon: 12 chemotherapy courses in the control arm versus 6 in the rituximab containing arm. | |||||||
| Marcus et al21,58 | 19 /41/40 | 52 | 53 | 15 (CVP) | 34 (R-CVP) | 50 (at 3 y) | Yes |
| Hiddemann et al59* | 14 /41/45 | 55 | 18 | 31 (CHOP) | Not reached (R-CHOP) | 80 (at 2 y) | Yes |
| Herold et al19† | 7/37/56 | 59 | 47 | 29 (CHOP) | Not reached (R-MCP) | 71 (at 4 y) | Yes |
| Salles et al60 (updated)‡ | 19/35/46 | 61 | 60 | 35 (CHVP+I) | Not reached (R-CHVP+I) | 53 (at 5 y) | Yes (in high-risk patients) |